The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.
This report covers the current and future global market for recombinant proteins, including a detailed analysis of the market's drivers, restraints and opportunities. The report also covers market projections for 2029, the market's competitive environment and companies' pipeline activities. The report delivers market estimates and forecasts for recombinant proteins categorized according to product type, host cell type, application, and region. Based on product type the market is segmented into hormones, cytokines, enzymes, antigens, antibodies, and others.
Based on the host cell type, recombinant proteins are categorized as mammalian, insect, yeast and fungi, bacterial, and other cell types. The market is segmented by application into therapeutics and vaccines, biomedical research, and diagnostics. The report includes the company profiles of the key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report does not cover proteins produced through hybridoma techniques. The report also excludes COVID-19 vaccines based on recombinant technology.
By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Regional analysis is further broken down by country as follows: North America - the U.S. and Canada; Europe - Germany, the U.K., France, Italy, and the Rest of Europe; Asia-Pacific - China, Japan, India, and the Rest of Asia-Pacific. For market estimates, data have been provided for 2021 and 2022 as the historic years, 2023 as the base year, and a forecast through 2029.
Report Includes
45 data tables and 46 additional tables
Analysis of the global market for recombinant proteins
Analyses of the global market trends, with market revenue data for 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
Discussion of the market drivers, restraints and opportunities
Estimate of the current market size and revenue prospects, along with a market share analysis by product (protein type), host cell type, application and region
Facts and figures pertaining to the market dynamics, current and emerging technologies, regulatory scenario, and the expected impact of macroeconomic factors
Overview of sustainability and ESG trends, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
Analysis of recent patents and pipeline activity
A look at the industry structure, including companies' market shares, M&A activity and venture funding
Company profiles of major players within the industry, including Novo Nordisk A/S, Lilly, Sanofi, and Amgen Inc.
Company Profiles
Amgen Inc.
Bayer Ag
F. Hoffmann-La Roche Ltd.
Lilly
Merck Kgaa
Novo Nordisk A/S
Pfizer Inc.
Sandoz Group Ag
Sanofi
Takeda Pharmaceutical Co. Ltd.
Key Attributes:
Report Attribute
Details
No. of Pages
108
Forecast Period
2024 - 2029
Estimated Market Value (USD) in 2024
$132.4 Billion
Forecasted Market Value (USD) by 2029
$203.6 Billion
Compound Annual Growth Rate
7.5%
Regions Covered
Global
Key Topics Covered:
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Types of Expression Host Systems
Mechanism of Action of Recombinant Proteins
Agonists
Antagonists
Common Steps Involved in Recombinant Protein Production
Chapter 3 Market Dynamics
Drivers
Growing R&D Investments in Biopharmaceuticals
Increasing Demand for Non-Hybridoma Techniques
Restraints
High Production Costs
Post-Translational Modifications and Protein Stability
Opportunities
Diagnostic and Therapeutic Applications of Recombinant Antibodies
Continuous Manufacturing and Improving Product Yields
Chapter 4 Emerging Technologies and Developments
Overview
Emerging Technologies
Protein-Engineering Advances
CRISPR Genome Editing
Cell-Free Protein Synthesis
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Recombinant Proteins, by Product Type
Hormones
Cytokines
Enzymes
Antibodies
Antigens
Global Market for Recombinant Proteins, by Host Cell Type
Bacterial Host Cells
Yeast and Fungi Cells
Mammalian Cells
Insect Cells
Other Cells
Global Market for Recombinant Proteins, by Application
Therapeutics and Vaccines
Biomedical Research
Diagnostics
Geographic Breakdown
Chapter 6 Competitive Intelligence
Competitive Landscape
M&A Analysis
Clinical Trial Activities
Chapter 7 ESG Perspective in the Recombinant Proteins Market
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nubian Resources Ltd. ("Nubian" or the "Company") is pleased to announce the results of its annual and special meeting of shareholders (the "Meeting") held earlier today. A total of 25,851,321 common shares of the Company were represented at the...
Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, advises it has completed a shares-for-debt transaction with certain arm's length creditors...
Lowell Farms Inc. (the "Company") , a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, announces the resignation of Mr. Jamie Schniedwind, Chief...
Vicinity Motor Corp. ("Vicinity" or the "Company"), a North American supplier of commercial electric vehicles, today announces the granting of Deferred Share Units ("DSUs"). Certain Eligible Directors have requested...
PACIFIC COAST OIL TRUST (the "Trust"), a royalty trust formed by Pacific Coast Energy Company LP ("PCEC"), announced today that there will be no cash distribution to the holders of its units of beneficial interest of record on June 28, 2024 based on...
The Board of Trustees of First Trust Enhanced Equity Income Fund (the "Fund") , CUSIP 337318109, previously approved a managed distribution policy for the Fund (the "Managed Distribution Plan") in reliance on exemptive relief received from the...